Position in HALO
as of Jun 30, 2026
· filed Jul 31, 2026
Position Value
$1,227,430
+$252,293 QoQ
Shares Held
15,682
+3.9% QoQ
Ownership
0.014%
of shares outstanding
% of Portfolio
0.09%
of 13F equity value
Holder Rank
#293
of 664 holders
Holding Since
Dec 2022
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in HALO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Belpointe Asset Management LLC holds $13,833,173 across 13 Biotechnology names. HALO ranks #6 (8.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INCY |
Incyte Corp
|
25,423 | $2,881,951 | |
| 2 | TGTX |
Tg Therapeutics, Inc.
|
50,719 | $2,786,501 | |
| 3 | MRNA |
Moderna, Inc.
|
32,598 | $2,282,837 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
3,741 | $1,858,266 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,371 | $1,478,413 | |
| 6 | HALO |
Halozyme Therapeutics, Inc.
This page
|
15,682 | $1,227,430 | |
| 7 | CADL |
Candel Therapeutics, Inc.
|
52,778 | $543,613 | |
| 8 | RPRX |
Royalty Pharma plc
|
5,485 | $307,543 |
All Filings in HALO
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,227,430 | 15,682 | Shares | Sole | 2026-07-31 | |
| 2026-03-31 | $975,137 | 15,088 | Shares | Sole | 2026-04-28 | |
| 2025-12-31 | $536,044 | 7,965 | Shares | Sole | 2026-01-27 | |
| 2025-09-30 | $314,481 | 4,288 | Shares | Sole | 2025-11-03 | |
| 2024-09-30 | $252,027 | 4,403 | Shares | Sole | 2024-11-13 | |
| 2024-06-30 | $202,999 | 3,877 | Shares | Sole | 2024-08-02 | |
| 2023-03-31 | $47,279 | 1,238 | Shares | Sole | 2023-05-15 | |
| 2022-12-31 | $49,616 | 872 | Shares | Sole | 2023-02-08 | |
| No filing history on record for this holder in this stock. | ||||||